Anaesthesia
Conditions
Interventions
Bupivacaine and Dexamethasone Group
Bupivacaine Group
Sponsors
Orotta College of Medicine and Health Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adult patients of either male or female, Age 18 to 80 years, ASA I or II patients, Elective orthopedic surgery such as elbow, forearm and hand under supraclavicular brachial plexus block
Exclusion criteria
Exclusion criteria: Patient refusal, Contraindication to SCBPB block such as severe chronic obstructive pulmonary disease, infection, Contralateral diaphragmatic paralysis, Neuropathy of the surgical limb, Pregnant women, Any bleeding disorder, Local infection at the injection site, Known allergy to LAs, Long term steroid therapy, Patients taking Opioids, Ketamine, NSAID during study period Diabetes mellitus, Hepatic and Renal disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The addition of dexamethasone 8 mg IV to 0.5% bupivacaine in supraclavicular brachial plexus block prolongs the duration of analgesia in the postoperative period significantly when compared to use of bupivacaine alone | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcomes can be explained by the secondary effect of the provided interventions. On top of the primary outcome, they also have a secondary outcome on the patient conditions such as fastens the onset of action of sensory and motor block and reduce the postoperative analgesic consumption. | — |
Countries
Eritrea
Contacts
Public ContactSabri Hashim
Publc Enquiries
Outcome results
None listed